Evidence map›Paper›PMID 26508167›Full record

ArticleEuropean heart journal2016

Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.

Stefanie Lip, Panniyammakal Jeemon, Linsay McCallum, Anna F Dominiczak, Gordon T McInnes, Sandosh Padmanabhan

Abstract read
In one paragraph

Article in European heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Type 2 Diabetes and Thiazide Diuretics.Current diabetes reports · 2018
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Stefanie LipInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK.
Panniyammakal JeemonInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK.
Linsay McCallumInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK.
Anna F DominiczakInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK.
Gordon T McInnesInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK.
Sandosh PadmanabhanInstitute of Cardiovascular and Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK sandosh.padmanabhan@glasgow.ac.uk.

Funding

British Heart Foundation CS/16/1/31878British Heart Foundation FS/14/52/30901DBT-Wellcome Trust India Alliance IA/CPHI/14/1/501497Wellcome Trust
6 · The paper itself

Abstract

aimsHypertension and diabetes mellitus (DM) frequently cluster together and synergistically increase cardiovascular risk. Among those who develop DM during treatment for hypertension (new-onset diabetes, NOD), it is unclear whether NOD reflects a separate entity associated with increased risk or merely reflects accelerated presentation of DM. METHODS AND

resultsWe analysed data on 15 089 hypertensive patients attending the Glasgow Blood Pressure Clinic. The date at first hospital encounter either with diagnosis of diabetes or prescription of anti-hyperglycaemic medication were considered as the onset of diabetes. Cox proportional hazard models (including propensity score matching) were employed to study associations between diabetes status, early and late NOD (diagnosis <10 years or >10 years from first clinic visit) and cause-specific mortality. There were 2516 patients (16.7%) with DM, of whom 1862 (12.3%) had NOD [early NOD = 705 (4.6%); late NOD = 1157 (7.6%)]. The incidence rate of NOD was 8.2 per 1000 person-years. The total time at risk was 239 929 person-years [median survival: 28.1 years (inter-quartile range: 16.2-39.9)]. Compared with non-diabetic individuals, prevalent DM [hazard ratio (HR) = 1.8, 95% confidence interval (CI): 1.4-2.2] and time varying NOD status (HR: 1.09, 95% CI: 1.06-1.17) were associated with increased adjusted all-cause mortality. Early NOD (HR: 1.39, 95% CI: 1.2-1.6) was associated with increased in mortality risk, but not late NOD (HR: 0.92, 95% CI: 0.83-1.01). Results were consistent in the propensity score matched analyses.

conclusionAlthough 1-in-8 hypertensive patients develop NOD, mortality is increased only in the 1-in-20 who develop early NOD. Further studies are warranted to determine if early identification of such individuals should provide an alert for intensification of therapeutic interventions.

Indexed as

Age of OnsetAntihypertensive AgentsDiabetic AngiopathiesFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedRisk FactorsScotlandTreatment OutcomeAntihypertensive AgentsHypertensionMortalityNew-onset diabetes mellitusPre-diabetes

Identifiers

PMID26508167
PMCPMC5841224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.